Research programme: gene editing based therapeutics - Casebia Therapeutics

Drug Profile

Research programme: gene editing based therapeutics - Casebia Therapeutics

Alternative Names: CRISPR/Cas9 gene editing therapies - Bayer-CRISPR Therapeutics

Latest Information Update: 01 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Casebia Therapeutics
  • Class Cardiovascular therapies; Eye disorder therapies; Gene therapies
  • Mechanism of Action Gene modulators; Gene transference; Immunogenetic modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Blindness; Congenital heart defects; Haematological disorders; Immunodeficiency disorders

Most Recent Events

  • 25 Jul 2017 University of California, University of Vienna and Charpentier submit appellate brief seeking reversal of decision by PTAB, which dismissed interference proceedings against Broad Institute, MIT and Harvard University for a patent related to CRISPR-Cas9 genome editing technology, in USA
  • 17 Apr 2017 Casebia Therapeutics signs a collaboration agreement with StrideBio to develop gene editing based therapeutics
  • 13 Apr 2017 University of California, University of Vienna, and Charpentier appeals decision by PTAB, which dismissed interference proceedings against Broad Institute, MIT, and Harvard University for a patent related to CRISPR-Cas9 genome editing technology, in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top